Partial agonists may have more positive effects as PPARγ ligands in diabetes by decreasing adverse effects caused by the activation of unwanted transcription, favored by the binding of full agonists, and by preventing Cdk5-mediated PPARγ phosphorylation, improving insulin sensitivity. Here, CDK5 is linked to diabetes mellitus.